Business
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE:
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"SHANGHAI, China and REDWOOD CITY, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that data presentations of four toripalimab pivotal clinical studies will be presented at the upcoming ASCO Annual Meeting, which is being held from June 2-6, 2023 at McCormick Place in Chicago. Presentations Abstract #6009/Poster #1: “Final Overall Survival Analysis of JUPITER-02: a Phase 3 study of Toripalimab versus Placebo in Combination with Gemcitabine and Cisplatin as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)”Principal Investigator: Prof. Rui-hua XU, Sun Yat-sen University Cancer CenterPoster Discussion Session: Head and Neck CancerDate: Monday, June 5, 2023, 4:30 p.m. Central Daylight Time Abstract #9003: “Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations”Principal Investigator: Prof. Jie WANG, Cancer Hospital, Chinese Academy of Medical SciencesOral Abstract Session: Lung Cancer-Non-Small Cell MetastaticDate and Time: Tuesday, June 6, 2023, 9:45 a.m. Central Daylight Time Abstract #8501: “Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study”Principal Investigator: Prof. Shun LU, Shanghai Chest HospitalOral Abstract Session: Lung Cancer-Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersDate and Time: Saturday, June 3, 2023, Session: 3:00-6:00 p.m., Presentation: 3:12 p.m. Central Daylight Time Abstract #LBA1013: “TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)”Principal Investigator: Prof. Zefei JIANG, Chinese PLA General HospitalRapid Abstract Session: Breast Cancer-Local/Regional/AdjuvantDate and Time: Saturday, June 3, 2023, Session: 4:30-5:30 p.m., Presentation: 4:54 p.m. Central Daylight Time The FDA has granted Breakthrough Therapy designations and priority review for th...